A Study to Evaluate PDS0101 Monotherapy for the Treatment of High Grade Cervical Dysplasia
Latest Information Update: 05 Nov 2019
At a glance
- Drugs PDS 0101 (Primary)
- Indications Cervical dysplasia; Cervical intraepithelial neoplasia
- Focus Registrational; Therapeutic Use
- Sponsors PDS Biotechnology Corporation
Most Recent Events
- 01 Oct 2019 According to a PDS Biotechnology Corporation media release, the company anticipates no longer to initiate this monotherapy study.
- 01 Oct 2019 Status changed from planning to withdrawn prior to enrolment, according to a PDS Biotechnology Corporation media release.
- 26 Mar 2019 New trial record